The annual general meeting of shareholders of Hepsor AS (registry code 12099216, address Järvevana 7b, 10112 Tallinn) was held on Wednesday, 21 May 2025 at 14:00 in the conference centre of Ibis Styles Tallinn located at Toompuiestee 19, Tallinn. The notice of convening the ordinary general meeting of shareholders was published on 29 April 2025 in the newspaper Postimees and on 28 April 2025 as a stock exchange news through the information system of Nasdaq Tallinn Stock Exchange. Therefore, the meeting was ...

文章核心观点 2025年5月20日在瑞士普拉特尔恩举行的年度股东大会上，Santhera Pharmaceuticals股东以绝大多数赞成票批准了董事会提出的所有议案，参会股东代表5073050股，占公司股本的37.5% [1] 分组1：报告与财务相关 - 股东批准了2024年年度报告、年度财务报表和合并财务报表，以及年度结果的分配和与自由储备的抵销 [2] - 股东批准将员工参与的有条件资本增加63000瑞士法郎，至111280.20瑞士法郎 [3] - 股东在咨询投票中认可了2024年薪酬报告，并在单独的具有约束力的投票中同意了董事会成员和执行管理层的薪酬 [5] 分组2：人员选举相关 - 股东再次选举Thomas Meier、Philipp Gutzwiller和Bradley C. Meyer为董事会成员，任期一年 [4] - 股东再次选举Thomas Meier为董事会主席，并批准选举Melanie Rolli为董事会成员 [4] - 股东确认Thomas Meier和Bradley C. Meyer为提名与薪酬委员会成员，Bradley C. Meyer担任委员会主席 [4] 分组3：其他信息 - 所有议案的详细信息和相关解释可在公司网站查看，2025年年度股东大会会议记录将于下周末结束后公布 [6] - 公司是一家专注于开发和商业化治疗罕见神经肌肉疾病创新药物的瑞士专业制药公司，AGAMREE®已在多个国家和地区获批，公司已将其相关权利授权给其他公司 [7]

Presentation of the work of the Nomination Committee The Nomination Committee was elected at the Annual General Meeting (“AGM”) on 14 May 2024 to be comprised of Robert N. Keith (Chair), Rune Sundvall and Christian Schlytter-Henrichsen. While the Nomination Committee was in the process of finalizing its proposal to the 2025 Annual General Meeting, two of the committee members, Rune Sundvall and Christian Schlytter-Henrichsen, resigned from the committee with immediate effect (although Rune Sundvall had prov ...

The Annual General Meeting of Telia Lietuva, AB (hereinafter 'the Company' or 'Telia Lietuva') shareholders was held on 28 April 2025. The Annual General Meeting of Telia Lietuva decided: - To approve the audited annual financial statements of the Company for the year 2024. The annual report of the Company for the year 2024, prepared by the Company, assessed by the auditors and approved by the Board, was presented to the shareholders. - To allocate the Company's profit for the year 2024: from the Company's ...